Owen Dean1, Alexandra Buda1, Heather R Adams2, Sylvia Mwanza-Kabaghe3, Michael J Potchen4, Esau G Mbewe3, Pelekelo P Kabundula3, Sarah Mohajeri Moghaddam4, Gretchen L Birbeck5, David R Bearden6. 1. University of Rochester School of Medicine, Rochester, New York. 2. Division of Child Neurology, Department of Neurology, University of Rochester School of Medicine, Rochester, New York. 3. Department of Psychology, University of Zambia, Lusaka, Zambia. 4. Department of Radiology, University of Rochester School of Medicine, Rochester, New York. 5. Division of Epilepsy, Department of Neurology, Rochester, New York; Department of Medicine, University of Zambia School of Medicine, Lusaka, Zambia. 6. Division of Child Neurology, Department of Neurology, University of Rochester School of Medicine, Rochester, New York. Electronic address: David_bearden@urmc.rochester.edu.
Abstract
BACKGROUND: Cognitive impairment is common in children and adolescents with human immunodeficiency virus (HIV). Brain magnetic resonance imaging (MRI) is a potentially useful tool to investigate the pathophysiology of HIV-associated cognitive impairment and may serve as a biomarker in future clinical trials. There are few published data on brain imaging in children with HIV in sub-Saharan Africa. METHODS: Thirty-four perinatally infected subjects with HIV and age-matched HIV-exposed uninfected controls between the ages nine and 17 years were recruited from the Pediatric Center of Excellence in Lusaka, Zambia, as part of the HIV-associated Neurocognitive Disorders in Zambia study. Brain MRI sequences were acquired, and clinical and volumetric assessments were performed. Subjects underwent a comprehensive neuropsychologic battery, and cognitive impairment status was classified using a global deficit score approach. Regression models were used to evaluate relationships between MRI findings and cognitive function. RESULTS: We identified cerebrovascular disease in seven of 34 subjects with HIV compared with zero of 17 controls (21% vs 0%, P = 0.04). We also identified decreased total brain volumes (1036 vs 1162 cm3, P = 0.03) and decreased cortical thickness in the right temporal lobes (3.12 vs 3.29 mm; P = 0.01) and right fusiform gyri (3.10 vs 3.25 mm; P = 0.02) of HIV-infected subjects with cognitive impairment. CONCLUSIONS: These findings support the hypothesis that brain volumes may be useful biomarkers for cognitive outcomes in children with HIV. Further studies are necessary to investigate mechanisms of cerebrovascular disease and volume loss in children with HIV.
BACKGROUND:Cognitive impairment is common in children and adolescents with human immunodeficiency virus (HIV). Brain magnetic resonance imaging (MRI) is a potentially useful tool to investigate the pathophysiology of HIV-associated cognitive impairment and may serve as a biomarker in future clinical trials. There are few published data on brain imaging in children with HIV in sub-Saharan Africa. METHODS: Thirty-four perinatally infected subjects with HIV and age-matched HIV-exposed uninfected controls between the ages nine and 17 years were recruited from the Pediatric Center of Excellence in Lusaka, Zambia, as part of the HIV-associated Neurocognitive Disorders in Zambia study. Brain MRI sequences were acquired, and clinical and volumetric assessments were performed. Subjects underwent a comprehensive neuropsychologic battery, and cognitive impairment status was classified using a global deficit score approach. Regression models were used to evaluate relationships between MRI findings and cognitive function. RESULTS: We identified cerebrovascular disease in seven of 34 subjects with HIV compared with zero of 17 controls (21% vs 0%, P = 0.04). We also identified decreased total brain volumes (1036 vs 1162 cm3, P = 0.03) and decreased cortical thickness in the right temporal lobes (3.12 vs 3.29 mm; P = 0.01) and right fusiform gyri (3.10 vs 3.25 mm; P = 0.02) of HIV-infected subjects with cognitive impairment. CONCLUSIONS: These findings support the hypothesis that brain volumes may be useful biomarkers for cognitive outcomes in children with HIV. Further studies are necessary to investigate mechanisms of cerebrovascular disease and volume loss in children with HIV.
Authors: Jason G van Genderen; Cecilia Chia; Malon Van den Hof; Henk J M M Mutsaerts; Liesbeth Reneman; Dasja Pajkrt; Anouk Schrantee Journal: Neurology Date: 2022-08-08 Impact factor: 11.800
Authors: Gauri Patil; Esau G Mbewe; Pelekelo P Kabundula; Hannah Smith; Sylvia Mwanza-Kabaghe; Alexandra Buda; Heather R Adams; Michael J Potchen; Milimo Mweemba; Brent A Johnson; Giovanni Schifitto; Handy Gelbard; Gretchen L Birbeck; David R Bearden Journal: J Acquir Immune Defic Syndr Date: 2022-10-01 Impact factor: 3.771
Authors: Pelekelo P Kabundula; Esau G Mbewe; Sylvia Mwanza-Kabaghe; Gretchen L Birbeck; Milimo Mweemba; Bo Wang; J Anitha Menon; David R Bearden; Heather R Adams Journal: AIDS Behav Date: 2022-04-21
Authors: Colleen L Schneider; Sarah Mohajeri-Moghaddam; Esau G Mbewe; Pelekelo P Kabundula; Owen Dean; Alexandra Buda; Michael J Potchen; Sylvia Mwanza-Kabaghe; Deanna Saylor; Heather R Adams; Gretchen L Birbeck; David R Bearden Journal: Pediatr Neurol Date: 2020-08-05 Impact factor: 3.372
Authors: Esau G Mbewe; Pelekelo P Kabundula; Sylvia Mwanza-Kabaghe; Alexandra Buda; Heather R Adams; Colleen Schneider; Michael J Potchen; Milimo Mweemba; Manoj Mathews; J Anitha Menon; Bo Wang; Travis Baseler; Alex Paciorkowski; Gretchen L Birbeck; David R Bearden Journal: J Acquir Immune Defic Syndr Date: 2022-01-01 Impact factor: 3.771
Authors: C Paula Lewis-de Los Angeles; Paige L Williams; Lisanne M Jenkins; Yanling Huo; Kathleen Malee; Kathryn I Alpert; Kristina A Uban; Megan M Herting; John G Csernansky; Sharon L Nichols; Russell B Van Dyke; Elizabeth R Sowell; Lei Wang Journal: Neuroimage Clin Date: 2020-03-16 Impact factor: 4.881
Authors: Jason G van Genderen; Malon Van den Hof; Anders C Boyd; Matthan W A Caan; Ferdinand W N M Wit; Peter Reiss; Dasja Pajkrt Journal: PLoS One Date: 2020-10-28 Impact factor: 3.240